Bayesian Synthesis Finds LAAO Fails Stroke Non-Inferiority Versus Anticoagulation

For cardiology and anticoagulation pharmacists, this Bayesian pooled analysis quantifies the probability that percutaneous left atrial appendage occlusion matches oral anticoagulation for stroke prevention, and confirms its durable but partial bleeding advantage.

left atrial appendage occlusionLAAOWatchmanWatchman FLXAmplatzer Amuletoral anticoagulationDOACwarfarinatrial fibrillationstroke preventionBayesian meta-analysisbleedingsecondary prevention Cardiology / Anticoagulation

Background Information

LAAO reduces bleeding but not strokes compared to anticoagulation.

Stroke prevention in atrial fibrillation requires balancing anticoagulation efficacy and bleeding risk. Left atrial appendage occlusion (LAAO) showed no significant advantage in stroke or systemic embolism (SSE) prevention over oral anticoagulation (OAC) but did reduce non-procedural clinically relevant bleeding (CRB). While LAAO may reduce bleeding, it does not clearly outperform OAC in preventing SSE, indicating heterogeneity and the need for patient-specific considerations. LAAO may reduce bleeding but lacks clear stroke prevention superiority over OAC.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Athmakuri KS, Nandyal SR, Pamreddy HR, Vinjamuri S, Lingamsetty SSP, Mahajan AV, Hussain M, Chaliki HP, Srivathsan K

Citation: Athmakuri KS, Nandyal SR, Pamreddy HR, et al. Comparative evaluation of left atrial appendage occlusion and oral anticoagulation: a Bayesian meta-analysis of randomized controlled trials. Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology. 2026;28(7). doi:10.1093/europace/euag163

Article Links: PubMed · Journal / DOI

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →